Shots:
- Roivant to acquire Silicon for $450M in Roivant’s equity with additional potential regulatory and commercial milestones. The acquisition will strengthen Roivant’s AI capabilities for drug discovery
- The acquisition of Silicon will bolster Roivant’s targeted protein degradation platform that will be powered by VantAI’s ML techniques
- The integration of Silicon and VantAI will allow Roivant to leverage both computational physics and machine learning-based approaches to drug design
Click here to read full press release/ article | Ref: PRNewswire | Image: PRNewswire
The post Roivant to Acquire Silicon Therapeutics for ~$450M first appeared on PharmaShots.
